Teva Pharmaceutical CEO to Highlight Growth Strategy at Key Investor Conferences
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is ramping up its investor outreach, with President and CEO Richard Francis scheduled to present at three major healthcare conferences in March 2026. These appearances signal a continued focus on communicating the company’s transformation and growth trajectory to the financial community.
Upcoming Conference Schedule
Francis will participate in the following events:
- UBS European Healthcare Conference: Tuesday, March 3, 2026 (investor meetings only)
- Leerink Partners Global Healthcare Conference: Monday, March 9, 2026, at 10:00 am ET (webcast fireside chat)
- Barclays 28th Annual Global Healthcare Conference: Tuesday, March 10, 2026, at 8:00 am ET (webcast fireside chat)
Live webcasts of the Leerink and Barclays presentations will be available on Teva’s Investor Relations website: https://ir.tevapharm.com/Events-and-Presentations. Archived webcasts will be accessible for 30 days.
Teva’s “Pivot to Growth” and Strategic Focus
These conference appearances come as Teva continues to execute its “Pivot to Growth” strategy. The company is transitioning from a primarily generics-focused business to a leading innovative biopharmaceutical company, while still leveraging its world-class generics capabilities. This shift includes a focus on neuroscience and immunology, as well as the development of complex generic medicines, and biosimilars.
Recent developments, such as the submission of its New Drug Application (NDA) for an extended-release injectable suspension of Olanzapine, demonstrate progress in this transformation. This formulation aims to address an unmet need in schizophrenia treatment, potentially representing a significant revenue opportunity.
Investor Confidence and Market Positioning
Teva’s active engagement with investors through these conferences underscores its commitment to transparency and shareholder communication. Presentations by CEO Richard Francis provide a platform to articulate the company’s vision, address investor concerns, and highlight key growth drivers.
The company’s focus on expanding its innovative and biosimilar medicines pipeline, alongside maintaining a strong generics portfolio, is intended to position Teva for sustained growth and profitability. This dual approach aims to balance the stability of the generics business with the higher-margin potential of innovative therapies.
Forward-Looking Statements and Risk Factors
As with any publicly traded company, Teva’s communications include cautionary notes regarding forward-looking statements. These statements are subject to risks and uncertainties that could impact future performance. Factors influencing Teva’s success include competition, intellectual property protection, debt levels, and regulatory compliance.
Contact Information
Media inquiries can be directed to [email protected]. Investor relations inquiries should be sent to [email protected].
FAQ
Q: Where can I find the webcasts of Teva’s conference presentations?
A: Live and archived webcasts will be available on Teva’s Investor Relations website: https://ir.tevapharm.com/Events-and-Presentations.
Q: What is Teva’s “Pivot to Growth” strategy?
A: It’s a transformation from a primarily generics company to a leading innovative biopharmaceutical company, leveraging its generics business.
Q: What is Olanzapine and why is Teva’s formulation significant?
A: Olanzapine is a commonly prescribed medication for schizophrenia. Teva’s extended-release injectable formulation aims to offer a more convenient and effective treatment option with potential advantages over existing therapies.
